InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,893.62
(
0.39%
)
US TECH 100
19,992.00
(
0.65%
)
Dow Jones
43,389.60
(
-0.13%
)
Brent Oil
72.94
(
3.15%
)
Bitcoin
90,849.85
(
1.09%
)
Post# of 1493
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

guchu

Send PM Follow Ignore
Followers 3
Posts 389
Boards Moderated 0
Alias Born 02/23/2016

guchu

Re: None

Thursday, 06/09/2016 12:53:29 PM

Thursday, June 09, 2016 12:53:29 PM

Post# of 1493
Orexigen Stock Gains More than 50% on Markman Hearing

main points:

1) shares shot up 51.6% on a favorable Markman hearing in the company’s patent infringement lawsuit against Actavis

2)Orexigen is currently working on growing sales of the product. Following the acquisition of U.S. rights, the company is looking to adopt a targeted approach in growing Contrave sales. Orexigen will focus on differentiating Contrave from generic amphetamines and will work on improving the gross to net ratio through managed care and pharmacy discount strategies. Contrave should benefit from a more targeted sales effort. The company is planning a third quarter relaunch and expects Contrave to achieve market share of 10% - 11% by 2018. Orexigen is hiring 160 sales reps to promote the product.

https://www.zacks.com/stock/news/219826/orexigen-stock-gains-more-than-50-on-markman-hearing?cid=CS-MKTWTCH-HL-219826
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up